Other malignant T cell-specific molecular markers, such as KIR3DL2 (CD158k), have shown promising efficacy as therapeutic targets, tending to be expressed in Sézary cells or in patients with late-stage MF (8, 9). The gene discussed is KIR3DL2; the disease is mycosis fungoides.